par Cortes, Javier;Vahdat, L.;Blum, J.;Twelves, Chris J;Campone, M.;Roche, Henri;Bachelot, Thomas;Awada, Ahmad ;Paridaens, R. ;Goncalves, A.;Shuster, D.;Wanders, Jantien;Fang, F.;Gurnani, R.;Richmond, E.;Cole, Patricia E;Ashworth, Simon;Allison, M.
Référence Journal of clinical oncology, 28, 25, page (3922-3928)
Publication Publié, 2010-09
Référence Journal of clinical oncology, 28, 25, page (3922-3928)
Publication Publié, 2010-09
Article révisé par les pairs
Titre: |
|
Auteur: | Cortes, Javier; Vahdat, L.; Blum, J.; Twelves, Chris J; Campone, M.; Roche, Henri; Bachelot, Thomas; Awada, Ahmad; Paridaens, R.; Goncalves, A.; Shuster, D.; Wanders, Jantien; Fang, F.; Gurnani, R.; Richmond, E.; Cole, Patricia E; Ashworth, Simon; Allison, M. |
Informations sur la publication: | Journal of clinical oncology, 28, 25, page (3922-3928) |
Statut de publication: | Publié, 2010-09 |
Sujet CREF: | Cancérologie |
MeSH keywords: | Adult |
Aged | |
Aged, 80 and over | |
Antineoplastic Agents -- adverse effects -- therapeutic use | |
Breast Neoplasms -- drug therapy -- pathology | |
Disease-Free Survival | |
Drug Administration Schedule | |
Ethers, Cyclic | |
Female | |
Furans -- adverse effects -- therapeutic use | |
Humans | |
Ketones -- adverse effects -- therapeutic use | |
Middle Aged | |
Peripheral Nervous System Diseases -- chemically induced | |
Retreatment | |
Note générale: | Clinical Trial, Phase II |
Journal Article | |
Multicenter Study | |
Research Support, Non-U.S. Gov't | |
Langue: | Anglais |
Identificateurs: | urn:issn:0732-183X |
info:doi/10.1200/JCO.2009.25.8467 | |
info:pii/JCO.2009.25.8467 | |
info:pmid/20679609 |